Compare ABCL & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABCL | FSK |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2020 | 2008 |
| Metric | ABCL | FSK |
|---|---|---|
| Price | $11.22 | $12.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | $8.40 | ★ $13.19 |
| AVG Volume (30 Days) | ★ 9.1M | 2.2M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 18.82% |
| EPS Growth | ★ 10.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,128,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 160.56 | N/A |
| 52 Week Low | $2.75 | $9.72 |
| 52 Week High | $12.58 | $18.21 |
| Indicator | ABCL | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 59.64 |
| Support Level | $10.44 | $10.41 |
| Resistance Level | N/A | $12.71 |
| Average True Range (ATR) | 0.78 | 0.24 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 42.16 | 52.05 |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.